Picture of Lixte Biotechnology Holdings logo

LIXT Lixte Biotechnology Holdings Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Annual cashflow statement for Lixte Biotechnology Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-2.44-3.26-6.73-6.31-5.09
Non-Cash Items0.7491.252.61.550.773
Other Non-Cash Items
Changes in Working Capital0.018-0.118-0.0130.1550.021
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-1.67-2.13-4.14-4.61-4.29
Financing Cash Flow Items-0.010
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Cash from Financing Activities04.63.95.143.14
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-1.672.47-0.2460.53-1.15